<?xml version="1.0" encoding="utf-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:hal="http://hal.archives-ouvertes.fr/" xmlns:gml="http://www.opengis.net/gml/3.3/" xmlns:gmlce="http://www.opengis.net/gml/3.3/ce" version="1.1" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 http://api.archives-ouvertes.fr/documents/aofr-sword.xsd">
  <teiHeader>
    <fileDesc>
      <titleStmt>
        <title>HAL TEI export of hal-04449388</title>
      </titleStmt>
      <publicationStmt>
        <distributor>CCSD</distributor>
        <availability status="restricted">
          <licence target="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0 - Universal</licence>
        </availability>
        <date when="2026-05-26T10:51:13+02:00"/>
      </publicationStmt>
      <sourceDesc>
        <p part="N">HAL API Platform</p>
      </sourceDesc>
    </fileDesc>
  </teiHeader>
  <text>
    <body>
      <listBibl>
        <biblFull>
          <titleStmt>
            <title xml:lang="en">Differences in venous clot structures between hemophilic mice treated with emicizumab versus factor VIII or factor VIIIFc</title>
            <author role="aut">
              <persName>
                <forename type="first">Thibaud</forename>
                <surname>Sefiane</surname>
              </persName>
              <idno type="halauthorid">2446255-0</idno>
              <affiliation ref="#struct-1051122"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Hortense</forename>
                <surname>Maynadié</surname>
              </persName>
              <idno type="halauthorid">3050115-0</idno>
              <affiliation ref="#struct-1051122"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Carmen Escurola</forename>
                <surname>Ettingshausen</surname>
              </persName>
              <idno type="halauthorid">3050116-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Vincent</forename>
                <surname>Muczynski</surname>
              </persName>
              <idno type="halauthorid">590351-0</idno>
              <affiliation ref="#struct-1051122"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Xavier</forename>
                <surname>Heiligenstein</surname>
              </persName>
              <idno type="halauthorid">32313-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Julien</forename>
                <surname>Dumont</surname>
              </persName>
              <idno type="halauthorid">235800-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Olivier</forename>
                <surname>Christophe</surname>
              </persName>
              <email type="md5">6a8f578558cca6abd74cd62b8e8eff3c</email>
              <email type="domain">inserm.fr</email>
              <idno type="idhal" notation="string">olivier-christophe</idno>
              <idno type="idhal" notation="numeric">803237</idno>
              <idno type="halauthorid" notation="string">2056673-803237</idno>
              <idno type="ORCID">https://orcid.org/0000-0002-9080-6336</idno>
              <idno type="IDREF">https://www.idref.fr/164951555</idno>
              <affiliation ref="#struct-1051122"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Cécile</forename>
                <surname>Denis</surname>
              </persName>
              <email type="md5">ff3ae8a2837e82b329480f466fd6568a</email>
              <email type="domain">inserm.fr</email>
              <idno type="idhal" notation="string">cecile-v-denis</idno>
              <idno type="idhal" notation="numeric">736804</idno>
              <idno type="halauthorid" notation="string">14953-736804</idno>
              <idno type="RESEARCHERID">http://www.researcherid.com/rid/A-7649-2011</idno>
              <idno type="ORCID">https://orcid.org/0000-0001-5152-9156</idno>
              <idno type="IDREF">https://www.idref.fr/113257899</idno>
              <idno type="RESEARCHERID">http://www.researcherid.com/rid/http://www.researcherid.com/rid/A-7649-2011</idno>
              <affiliation ref="#struct-1051122"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Caterina</forename>
                <surname>Casari</surname>
              </persName>
              <email type="md5">cbbc3dc7d3470e5a7edbc23c67b53948</email>
              <email type="domain">inserm.fr</email>
              <idno type="idhal" notation="string">caterina-casari</idno>
              <idno type="idhal" notation="numeric">797969</idno>
              <idno type="halauthorid" notation="string">1698527-797969</idno>
              <idno type="ORCID">https://orcid.org/0000-0002-8271-6795</idno>
              <affiliation ref="#struct-1051122"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Peter</forename>
                <surname>Lenting</surname>
              </persName>
              <idno type="halauthorid">2196191-0</idno>
              <affiliation ref="#struct-1051122"/>
            </author>
            <editor role="depositor">
              <persName>
                <forename>caterina</forename>
                <surname>casari</surname>
              </persName>
              <email type="md5">cbbc3dc7d3470e5a7edbc23c67b53948</email>
              <email type="domain">inserm.fr</email>
            </editor>
          </titleStmt>
          <editionStmt>
            <edition n="v1" type="current">
              <date type="whenSubmitted">2024-03-14 12:46:07</date>
              <date type="whenModified">2026-03-31 17:50:08</date>
              <date type="whenReleased">2024-03-18 15:05:48</date>
              <date type="whenProduced">2024-03-14</date>
              <date type="whenEndEmbargoed">2024-03-14</date>
              <ref type="file" target="https://hal.science/hal-04449388v1/document">
                <date notBefore="2024-03-14"/>
              </ref>
              <ref type="file" subtype="greenPublisher" n="1" target="https://hal.science/hal-04449388v1/file/11374-Article%20Text-82868-2-10-20231219.pdf" id="file-4504577-3904647">
                <date notBefore="2024-03-14"/>
              </ref>
              <ref type="externalLink" target="https://haematologica.org/article/download/haematol.2023.284142/76386"/>
            </edition>
            <respStmt>
              <resp>contributor</resp>
              <name key="947754">
                <persName>
                  <forename>caterina</forename>
                  <surname>casari</surname>
                </persName>
                <email type="md5">cbbc3dc7d3470e5a7edbc23c67b53948</email>
                <email type="domain">inserm.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>
            <distributor>CCSD</distributor>
            <idno type="halId">hal-04449388</idno>
            <idno type="halUri">https://hal.science/hal-04449388</idno>
            <idno type="halBibtex">sefiane:hal-04449388</idno>
            <idno type="halRefHtml">&lt;i&gt;Haematologica&lt;/i&gt;, 2024, &lt;a target="_blank" href="https://dx.doi.org/10.3324/haematol.2023.284142"&gt;&amp;#x27E8;10.3324/haematol.2023.284142&amp;#x27E9;&lt;/a&gt;</idno>
            <idno type="halRef">Haematologica, 2024, &amp;#x27E8;10.3324/haematol.2023.284142&amp;#x27E9;</idno>
            <availability status="restricted">
              <licence target="https://about.hal.science/hal-authorisation-v1/">HAL Authorization<ref corresp="#file-4504577-3904647"/></licence>
            </availability>
          </publicationStmt>
          <seriesStmt>
            <idno type="stamp" n="APHP" corresp="INSERM">AP-HP</idno>
            <idno type="stamp" n="UNIV-PARIS-SACLAY">Université Paris-Saclay</idno>
            <idno type="stamp" n="UNIVERSITE-PARIS-SACLAY" corresp="UNIV-PARIS-SACLAY">Université Paris-Saclay</idno>
            <idno type="stamp" n="GS-LIFE-SCIENCES-HEALTH" corresp="UNIVERSITE-PARIS-SACLAY">Graduate School Life Sciences and Health</idno>
            <idno type="stamp" n="GS-HEALTH-DRUG-SCIENCES">Graduate School Health and Drug Sciences</idno>
            <idno type="stamp" n="HITH">Hémostase, inflammation, thrombose</idno>
            <idno type="stamp" n="PSACLAY-TEST">Université Paris-Saclay - Collection pour tests</idno>
          </seriesStmt>
          <notesStmt>
            <note type="audience" n="2">International</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="1">Yes</note>
          </notesStmt>
          <sourceDesc>
            <biblStruct>
              <analytic>
                <title xml:lang="en">Differences in venous clot structures between hemophilic mice treated with emicizumab versus factor VIII or factor VIIIFc</title>
                <author role="aut">
                  <persName>
                    <forename type="first">Thibaud</forename>
                    <surname>Sefiane</surname>
                  </persName>
                  <idno type="halauthorid">2446255-0</idno>
                  <affiliation ref="#struct-1051122"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Hortense</forename>
                    <surname>Maynadié</surname>
                  </persName>
                  <idno type="halauthorid">3050115-0</idno>
                  <affiliation ref="#struct-1051122"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Carmen Escurola</forename>
                    <surname>Ettingshausen</surname>
                  </persName>
                  <idno type="halauthorid">3050116-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Vincent</forename>
                    <surname>Muczynski</surname>
                  </persName>
                  <idno type="halauthorid">590351-0</idno>
                  <affiliation ref="#struct-1051122"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Xavier</forename>
                    <surname>Heiligenstein</surname>
                  </persName>
                  <idno type="halauthorid">32313-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Julien</forename>
                    <surname>Dumont</surname>
                  </persName>
                  <idno type="halauthorid">235800-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Olivier</forename>
                    <surname>Christophe</surname>
                  </persName>
                  <email type="md5">6a8f578558cca6abd74cd62b8e8eff3c</email>
                  <email type="domain">inserm.fr</email>
                  <idno type="idhal" notation="string">olivier-christophe</idno>
                  <idno type="idhal" notation="numeric">803237</idno>
                  <idno type="halauthorid" notation="string">2056673-803237</idno>
                  <idno type="ORCID">https://orcid.org/0000-0002-9080-6336</idno>
                  <idno type="IDREF">https://www.idref.fr/164951555</idno>
                  <affiliation ref="#struct-1051122"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Cécile</forename>
                    <surname>Denis</surname>
                  </persName>
                  <email type="md5">ff3ae8a2837e82b329480f466fd6568a</email>
                  <email type="domain">inserm.fr</email>
                  <idno type="idhal" notation="string">cecile-v-denis</idno>
                  <idno type="idhal" notation="numeric">736804</idno>
                  <idno type="halauthorid" notation="string">14953-736804</idno>
                  <idno type="RESEARCHERID">http://www.researcherid.com/rid/A-7649-2011</idno>
                  <idno type="ORCID">https://orcid.org/0000-0001-5152-9156</idno>
                  <idno type="IDREF">https://www.idref.fr/113257899</idno>
                  <idno type="RESEARCHERID">http://www.researcherid.com/rid/http://www.researcherid.com/rid/A-7649-2011</idno>
                  <affiliation ref="#struct-1051122"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Caterina</forename>
                    <surname>Casari</surname>
                  </persName>
                  <email type="md5">cbbc3dc7d3470e5a7edbc23c67b53948</email>
                  <email type="domain">inserm.fr</email>
                  <idno type="idhal" notation="string">caterina-casari</idno>
                  <idno type="idhal" notation="numeric">797969</idno>
                  <idno type="halauthorid" notation="string">1698527-797969</idno>
                  <idno type="ORCID">https://orcid.org/0000-0002-8271-6795</idno>
                  <affiliation ref="#struct-1051122"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Peter</forename>
                    <surname>Lenting</surname>
                  </persName>
                  <idno type="halauthorid">2196191-0</idno>
                  <affiliation ref="#struct-1051122"/>
                </author>
              </analytic>
              <monogr>
                <idno type="halJournalId" status="VALID">22186</idno>
                <idno type="issn">0390-6078</idno>
                <idno type="eissn">1592-8721</idno>
                <title level="j">Haematologica</title>
                <imprint>
                  <publisher>Ferrata Storti Foundation</publisher>
                  <date type="datePub">2024-03-14</date>
                </imprint>
              </monogr>
              <idno type="doi">10.3324/haematol.2023.284142</idno>
            </biblStruct>
          </sourceDesc>
          <profileDesc>
            <langUsage>
              <language ident="en">English</language>
            </langUsage>
            <textClass>
              <classCode scheme="halDomain" n="sdv">Life Sciences [q-bio]</classCode>
              <classCode scheme="halTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halOldTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halTreeTypology" n="ART">Journal articles</classCode>
            </textClass>
            <abstract xml:lang="en">
              <p>Recombinant factor VIII (rFVIII), rFVIIIFc and emicizumab are established treatment options in the management of hemophilia A. Each has its unique mode of action, which can influence thrombin generation kinetics and therefore also the kinetics of thrombin substrates. Such differences may potentially result in clots with different structural and physical properties. A starting observation of incomplete wound closure in a patient on emicizumab-prophylaxis led us employ a relevant mouse model in which we noticed that emicizumab-induced clots appeared less stable compared to FVIII-induced clots. We thus analyzed fibrin formation in vitro and in vivo. In vitro fibrin formation was faster and more abundant in the presence of emicizumab compared to rFVIII/rFVIIIFc. Furthermore, the time-interval between the initiation of fibrin formation and factor XIII activation was twice as long for emicizumab compared to rFVIII/rFVIIIFc. Scanning-electron microscopy and immunofluorescent spinning-disk confocal-microscopy of in vivo generated clots confirmed increased fibrin formation in the presence of emicizumab. Unexpectedly, we also detected a different morphology between rFVIII/rFVIIIFc- and emicizumab-induced clots. Contrary to the regular fibrin-mesh obtained with rFVIII/rFVIIIFc, fibrin-fibers appeared to be fused into large patches upon emicizumabtreatment. Moreover, fewer red blood cells were detected in regions where these fibrin patches were present. The presence of highly-dense fibrin-structures associated with a diffuse fiber-structure in emicizumab-induced clots was also observed when using superresolution imaging. We hypothesize that the modified kinetics of thrombin, fibrin and factor XIIIa generation contribute to differences in structural and physical properties between clots formed in the presence of FVIII or emicizumab.</p>
            </abstract>
          </profileDesc>
        </biblFull>
      </listBibl>
    </body>
    <back>
      <listOrg type="structures">
        <org type="laboratory" xml:id="struct-1051122" status="VALID">
          <idno type="RNSR">201521293J</idno>
          <orgName>Hémostase, Inflammation, Thrombose</orgName>
          <orgName type="acronym">HITH - U1176 Inserm - CHU Bicêtre</orgName>
          <date type="start">2020-01-01</date>
          <desc>
            <address>
              <addrLine>80 rue du Général Leclerc Bâtiment Grégory Pincus 94276 Le kremlin-bicêtre</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.umrs1176.u-psud.fr/</ref>
          </desc>
          <listRelation>
            <relation name="U1176" active="#struct-303623" type="direct"/>
            <relation active="#struct-312432" type="direct"/>
            <relation active="#struct-300068" type="indirect"/>
            <relation active="#struct-419361" type="direct"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-303623" status="VALID">
          <idno type="IdRef">026388278</idno>
          <idno type="ROR">https://ror.org/02vjkv261</idno>
          <orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
          <orgName type="acronym">INSERM</orgName>
          <desc>
            <address>
              <addrLine>101, rue de Tolbiac, 75013 Paris</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.inserm.fr</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-312432" status="VALID">
          <orgName>Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre]</orgName>
          <desc>
            <address>
              <addrLine>78 Rue du Général Leclerc 94270 Le Kremlin-Bicêtre</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://hopital-bicetre.aphp.fr/</ref>
          </desc>
          <listRelation>
            <relation active="#struct-300068" type="direct"/>
          </listRelation>
        </org>
        <org type="regroupinstitution" xml:id="struct-300068" status="VALID">
          <idno type="ROR">https://ror.org/00pg5jh14</idno>
          <orgName>Assistance publique - Hôpitaux de Paris (AP-HP)</orgName>
          <orgName type="acronym">AP-HP</orgName>
          <desc>
            <address>
              <country key="FR"/>
            </address>
          </desc>
        </org>
        <org type="institution" xml:id="struct-419361" status="VALID">
          <idno type="IdRef">241345251</idno>
          <idno type="ROR">https://ror.org/03xjwb503</idno>
          <orgName>Université Paris-Saclay</orgName>
          <desc>
            <address>
              <addrLine>Bâtiment Bréguet, 3 Rue Joliot Curie 2e ét, 91190 Gif-sur-Yvette</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.universite-paris-saclay.fr/fr</ref>
          </desc>
        </org>
      </listOrg>
    </back>
  </text>
</TEI>